Form 4: Inozyme Pharma Acquired by BioMarin Pharmaceutical in $4.00 Per Share Cash Merger

Inozyme Pharma, Inc. has been acquired by BioMarin Pharmaceutical Inc. for $4.00 per share in cash, with the merger effective July 1, 2025, resulting in the cancellation and cash conversion of outstanding equity awards.

Summary

• Inozyme Pharma, Inc. (INZY) was acquired by BioMarin Pharmaceutical Inc. through its wholly-owned subsidiary, Incline Merger Sub, Inc.
• The acquisition was completed via a cash tender offer for all outstanding shares of Inozyme Pharma common stock at a price of $4.00 per share.
• The merger became effective on July 1, 2025, with Inozyme Pharma continuing as the surviving corporation and a wholly-owned subsidiary of BioMarin Pharmaceutical Inc.
• Douglas A. Treco, CEO & Chairman of Inozyme Pharma, disposed of 43,861 shares of common stock at $4.00 per share as part of the merger.
• His 150,000 Restricted Stock Units (RSUs) were automatically accelerated, fully vested, and converted into a cash payment equal to the merger consideration ($4.00 per share).
• His outstanding Stock Options (Right to Buy) with per share exercise prices less than the merger consideration were automatically accelerated, fully vested, and converted into a cash payment equal to the excess of the merger consideration over the exercise price. This included 86,979 options with an exercise price of $2.77 and 400,000 options with an exercise price of $1.06.

Sentiment

Score: 7

Explanation: The sentiment is positive for shareholders who received a cash payout for their shares and equity awards, providing immediate liquidity and a defined return. However, it marks the end of Inozyme Pharma as an independent entity, which could be seen as neutral or slightly negative for those who preferred its standalone growth potential.

Positives

• Shareholders of Inozyme Pharma received a cash payment of $4.00 per share for their common stock, providing immediate liquidity.
• Outstanding Restricted Stock Units (RSUs) and in-the-money Stock Options held by reporting persons were automatically accelerated, fully vested, and converted into cash payments, ensuring a payout for equity award holders.

Negatives

• Inozyme Pharma, Inc. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of BioMarin Pharmaceutical Inc.
• Former shareholders no longer participate in any potential future upside or growth of Inozyme Pharma as an independent entity.

Risks

• The primary risk for former Inozyme Pharma shareholders is the loss of future growth potential and participation in the company's independent success, as it is now a wholly-owned subsidiary.

Future Outlook

Following the merger, Inozyme Pharma, Inc. will operate as a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., indicating a shift from independent public operations to integration within a larger pharmaceutical company.

Industry Context

This acquisition reflects the ongoing consolidation trend within the biotechnology and rare disease pharmaceutical sectors, where larger companies acquire smaller, specialized firms to expand their pipeline, intellectual property, and market reach. Such mergers often provide an exit strategy for early investors and liquidity for shareholders of the acquired entity.

Comparison to Industry Standards

• The acquisition of Inozyme Pharma by BioMarin Pharmaceutical Inc. at $4.00 per share is consistent with typical M&A activities in the biotech sector, where companies with promising drug candidates or platforms are acquired by larger players.
• While specific comparable companies or projects are not detailed, similar transactions often involve a premium over the pre-announcement trading price, reflecting the strategic value to the acquirer.
• Recent acquisitions like Pfizer's acquisition of Seagen or AbbVie's acquisition of ImmunoGen demonstrate the trend of larger pharmaceutical companies acquiring smaller biotech firms to bolster their oncology or rare disease portfolios, often at significant valuations.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $4.00 per share in cash, providing immediate liquidity and a defined return on investment.
• Employees: Future roles and employment terms will be subject to the integration plans of BioMarin Pharmaceutical Inc.
• Customers/Patients: Potential for continued or accelerated development of Inozyme Pharma's therapeutic programs under BioMarin's resources.

Next Steps

• Inozyme Pharma, Inc. will continue operations as a wholly-owned subsidiary of BioMarin Pharmaceutical Inc.
• Integration of Inozyme Pharma's operations and assets into BioMarin Pharmaceutical Inc.

Key Dates

Keywords

Inozyme Pharma, BioMarin Pharmaceutical, Merger, Acquisition, Tender Offer, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, INZY, Biotechnology, Pharmaceuticals